LLY Stock Price Today (August 2026) — Eli Lilly and Company Analysis & Key Metrics 2026-08-21
Eli Lilly and Company (LLY) is trading at $1255.40, up 0.88% today (as of August 2026). The stock continues to show sustained strength above key moving averages, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $1276.96 (1.7% upside).
- Volatility remains elevated (34.84% annualized), implying wide price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (55.50% YoY) alongside significant competitive pressures.
LLY Stock Analysis: Key Metrics & Valuation (August 2026)
Concise, actionable data for investors
Eli Lilly and Company - Historical Price & Volume
Market Cap
Enterprise Value: $1.03T
P/E Ratio
Forward P/E: 24.75
Revenue Growth
Year over Year
Analyst Target
+1.7% upside potential
Key Investor Questions About LLY
What investors need to know before buying
Based on current market data, LLY presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 61.52)
- Fundamentals say: Caution warranted (high leverage concerns)
LLY's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for LLY investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $43.37B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, LLY stock traded between $623.78 and $1249.45—recovering meaningfully from lows and currently near the higher end. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 34.84% annualized volatility and β=0.61, the stock exhibits low sensitivity to market moves—making LLY suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional backing, but elevated short interest signals a potential battleground stock.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Will Eli Lilly’s Global Vault CRM Deal and Leadership Shift Change Veeva Systems’ (VEEV) Narrative?
Veeva Systems recently secured Eli Lilly and Company’s commitment to deploy Veeva Vault CRM globally, while also announcing that President and Chief Customer Officer Thomas D. Schwenger will depart in October 2026, to be succeeded by Dan Rizzo as EVP of Sales, Consulting, and Services. These developments arrive as Wall Street analysts anticipate higher upcoming quarterly earnings and revenue for Veeva, highlighting how large client wins and leadership transitions could shape the company’s...
Eli Lilly (LLY) Is Up 6.4% After UK Clears Foundayo and GLP‑1 Portfolio Advances - What's Changed
Eli Lilly recently reported strong revenue growth driven by its Mounjaro and Zepbound obesity and diabetes drugs, raised full-year guidance, advanced its next-generation GLP-1 pipeline, and secured UK approval for Foundayo, its once-daily oral GLP-1 pill for weight management and type 2 diabetes. These developments, alongside vaccine research collaborations and ongoing legal action against unauthorized retatrutide sellers, highlight Lilly’s bid to extend its leadership across injectable,...
Eli Lilly Jumps as Weight-Loss Leadership Drives Another Breakout
Mounjaro and Zepbound are widening Lilly's advantage while its next-generation pipeline adds fresh growth options.
Bristol-Myers Squibb (BMY) Bets $2.3 Billion on Texas While Eli Lilly (LLY) Wins in the UK
Drugmaker Bristol-Myers Squibb Company (NYSE:BMY) is putting real money behind its confidence in American manufacturing. On August 10, the company said it will spend about $2.3 billion on a new plant in Houston, part of a larger $40 billion U.S. investment pledge. On the very same day, British regulators cleared Eli Lilly and Company (NYSE:LLY)’s […]
Lilly's Multiple Assumes Less Growth Than You Think
Consensus asks Eli Lilly for far less growth than it is delivering, and for margins to keep climbing from a level it only just reached.
Most Of What Moves AbbVie Stock Has Nothing To Do With The Market
What AbbVie sells, and who pays for it, is the useful way to read its low correlation to the index.
Stock Split Watch: Is Eli Lilly (LLY) Stock Next?
Shares recently traded at $1,280 each, so a split wouldn't be surprising.
Apple paid $17bn in taxes to Ireland after court ruling on back levies
Apple paid Ireland $17bn in taxes last year, representing 40 per cent of its worldwide total, according to filings that offer new insight into...
Pharma Stocks Have Rallied. 2 Stocks to Avoid—and 2 to Buy.
The exchange-traded fund, home to some large pharma companies and many smaller biotechs, has risen over 6% this week. The main catalyst was Moderna and Merck announcement of successful trial data for a melanoma vaccine that reduces the risk patients will experience recurrence. “The read-through [from Merck and Moderna] to the others is probably indicative of a broader tailwind of pharma taking some strong actions to improve their long-term growth profiles,” says Cantor Fitzgerald analyst Carter Gould.
Eli Lilly Is In A Race with Novo Nordisk But Its Stock Is The Clear Winner
Eli Lilly stock broke out of a flat base and reached a record high. Its Mounjaro drug sales surged 91% in the second quarter.
Explore More Analysis for LLY
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Frequently Asked Questions
Common investor questions about Eli Lilly and Company
Eli Lilly and Company (LLY) is currently trading at $1255.40. The RSI (14-day) is at 61.5, indicating neutral territory. Wall Street analysts have a consensus "buy" recommendation. The mean analyst price target of $1276.96 implies 1.7% upside from current levels. Volatility is moderate at 34.8% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Eli Lilly and Company (LLY): The trailing P/E ratio is 44.84, which is above the market average, indicating investors are pricing in higher growth expectations. The forward P/E is 24.75, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 1.61, near 1.0, suggesting roughly fair value relative to growth. Price-to-Book is 35.95. Price-to-Sales is 15.49. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 26 analysts covering LLY, the consensus price target is $1276.96. This represents a 1.7% upside from the current price of $1255.40. The range spans from a low target of $850.00 to a high target of $1600.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "buy". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Eli Lilly and Company (LLY) pays a dividend with a current yield of approximately 55.00%. The annualized dividend rate is $6.23 per share. The payout ratio is 22.1%, which is conservative and suggests the dividend is well-covered by earnings with room for future increases. The most recent ex-dividend date was 2026-08-14T00:00:00.000Z.
Key risks for Eli Lilly and Company (LLY) investors include: 1. Moderate volatility (34.8% annualized)—price swings are notable. 2. Elevated debt levels (D/E ratio of 139.01) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Eli Lilly and Company's (LLY) current debt and financial health profile: Total debt stands at $43.37B. The debt-to-equity ratio is 139.01, which is elevated and warrants monitoring, especially in a rising interest rate environment. The current ratio is 1.50, indicating strong short-term liquidity. The quick ratio is 0.72. The company holds $5.28B in cash and equivalents. Free cash flow is positive at $9.16B, providing a cushion for debt servicing and shareholder returns.